ASCO
ESMO
NHB
MCBS
Value assessment frameworks in oncology: championing concordance through shared standards
Summary
The ASCO Value Framework Net Health Benefit Score (ASCO-NHB) and the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS), introduced in 2015, are essential tools for assessing the relative benefit of cancer therapies. Both ASCO and ESMO continually refine these frameworks and engage with stakeholders to better understand and communicate the value of new treatments. As the global burden of cancer grows, their collaborative efforts aim to foster a coherent approach to managing and reducing this impact.
As rapidly evolving tools under the constant rigorous review and development by both ASCO and ESMO’s expert task forces, the ASCO Value Framework Net Health Benefit Score (ASCO-NHB) and the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) were both launched in 2015 to assess the relative benefit of cancer therapies and were recently compared. Both societies are working to better understand and measure the value of new cancer therapies and are facilitating a broader discussion with stakeholders that, hopefully, will lead to a coherent approach to confronting the global burden of cancer. The time to do so is now.....
Click for Source
ASCO, ESMO, NHB, MCBS
